46 min listen
Reformulating psychedelics for neurodegenerative diseases
Reformulating psychedelics for neurodegenerative diseases
ratings:
Length:
42 minutes
Released:
Mar 15, 2024
Format:
Podcast episode
Description
There is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential side effects for the patient.Our guest this week is Dr Sam Clark, who founded Terran Biosciences to develop a safe, effective portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. 00:52-04:09: About Terran Biosciences04:09-06:03: What are the challenges of using psychedelics?06:03-07:32: Is there still a stigma attached to use of psychedelics? 07:32-11:45: How do psychedelics work on the brain?11:45-13:44: Why are psychedelics a good treatment?13:44-16:51: What is Idazoxan XR?16:51-18:01: How do you make changes to drugs?18:01-21:19: How did you develop your business model?21:19-22:40: What are Eplivanserin and Volinanserin?22:40-24:49: How useful are repurposed drugs?24:49-29:06: Keeping drugs affordable29:06-30:31: Dealing with patents30:31-32:41: What are empathogens?32:41-33:12: Where is the company at with clinical trials?33:12-35:45: What is NM-101?35:45-37:47: How does Terran differ from other companies?37:47-39:54: Are you looking to cure conditions?39:54-40:48: SchizophreniaInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter
Released:
Mar 15, 2024
Format:
Podcast episode
Titles in the series (96)
Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma by Beyond Biotech - the podcast from Labiotech